CME Group heads into its May 14 Q1 results with the stock under pressure, analyst targets moving in conflicting directions, and valuation multiples in a quiet decline.
The most telling signal this week is in analyst activity, which has been unusually busy and split. Morgan Stanley maintained its Overweight rating but cut its target from $362 to $353 on April 23 — just one day after the company's Q1 print produced a muted one-day move of less than 0.4%. That restraint from a bullish, bellwether firm underlines the broader Street mood. Barclays has been even more active, adjusting its Equal-Weight target three times over the past four weeks, ending lower at $316 versus $344 a month ago. JP Morgan, meanwhile, holds an Underweight with a $266 target — a meaningful gap below the current price of $286.82. Against that, Piper Sandler bucked the tide, raising its Overweight target to $329 on April 15. The consensus mean settles at $306.60, implying just under 7% upside, but the direction of recent revisions has been more guarded than constructive.
Valuation supports the cautious read. The P/E multiple has compressed by roughly 2 full turns over the past 30 days, from around 25x to 23x. The price-to-book has also slipped by about 0.16x over the same window. EV/EBITDA of 20.2x is slightly lower than a month ago. These moves are modest in isolation, but they all point the same direction: the market is paying somewhat less for CME's earnings power heading into this next print. The bull case rests on eight consecutive percent-plus revenue growth, strong free cash flow, and a 14-year dividend growth streak — a dividend score in the 98th percentile confirms the yield story is holding up well, with a forward yield of roughly 4%. The bear case points to headwinds from rate-cutting cycles compressing interest rate futures volumes, plus pricing pressure from competitors including FMX. EPS forward growth ranks only in the 23rd percentile on a year-over-year basis, and the EV/EBIT factor score of 24 suggests the market is not pricing in much growth acceleration.
Positioning in the lending market tells a quiet story. Short interest at 1.35% of the free float is low — up about 2.1% over the past week and 5.1% over the past month, but those moves represent a small drift upward from an already modest base. For context, the mid-March peak sat closer to 1.9% before falling sharply through April; the current level is a modest re-accumulation off lows. Borrowing costs have eased, now running at 0.36% APR — down 14% on the week and 21% over the past month — after briefly spiking above 0.57% in mid-April. Availability in the lending pool is very loose. With short interest this low, there is no squeeze dynamic and no meaningful borrow constraint. The short score of 29.7 is stable and low, consistent with a stock that bears are monitoring but not aggressively targeting.
Options positioning has shifted toward a more balanced reading. The put/call ratio at 1.23 is below its 20-day average of 1.36, running 0.58 standard deviations below the mean — a notable move for a stock that spent much of April and March with PCR readings in the 1.5-1.9 range. That compression suggests options traders have reduced defensive hedges over the past two weeks, even as the stock has slipped 6% over the past month to $286.82. Peers give a mixed backdrop: CBOE surged 13.3% on the week while Tradeweb and MarketAxess both dropped roughly 2-4.5%, and ICE was flat. The divergence makes CME's modest 0.8% weekly gain harder to read as a sector signal.
With Q1 earnings scheduled for May 14, the setup reduces to one question: whether the recent ADV strength can offset interest rate headwind concerns enough to stabilise forward estimates. That is what the next print will answer.
See the live data behind this article on ORTEX.
Open CME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
